Dr. Robert Stein, MD, PhD
IAG’s Scientific Expert in preclinical development and translational medicine. Dr. Stein began his career at Merck, Sharp and Dohme. He holds an MD and a PhD in Physiology & Pharmacology from Duke University. Over his 30 years of experience in the biopharmaceutical industry he played a pivotal role in bringing to the market Sustiva®, Fablyn®, Viviant®, PanRetin®, TargRetin®, Promacta® and Eliquis®. Dr. Stein is helping our bio-pharmaceutical partners to shape clinical development strategy, discovery and optimization technology platforms and portfolio in oncology and immune-oncology programs.